By David Tuller, DrPH When the PACE trial was published in early 2011, my New York Times editor sent it to me, along with the press release. As a non-staff contributor to the Times, I had started covering the debate over the mouse retrovirus hypothesis and science, but I’d heard nothing about anything called PACE …
Trial By Error: My 2011 NY Times Exchange With the PACE PIs Read More »
By David Tuller, DrPH Earlier this month, in advance of a stakeholder meeting, the U.K.’s National Institute for Health and Care Excellence released a draft scoping report. The document outlined the issues slated to be addressed by the committee selected to develop the new guidance for the illness NICE now calls ME/CFS. (The 2007 guidance …
Trial By Error: NICE’s Consideration of the Lightning Process Read More »
By David Tuller, DrPH It’s been almost a year since the CDC removed its recommendations for GET and CBT as treatments for ME/CFS (or CFS, or ME, or CFS/ME, or even SEID or whatever else one calls this illness or cluster of illnesses). When questioned about the decision, the agency explained that people had misunderstood …
Trial By Error: More on the CDC; Reader’s Digest; and BBC’s Newsbeat Read More »
By David Tuller, DrPH Last year, BMJ Open published a paper called Randomised controlled trial of online continuing education for health professionals to improve the management of chronic fatigue syndrome: a study protocol. The seven authors, all affiliated with the University of New South Wales in Sydney, included Professor Andrew Lloyd, the infectious disease expert …
Trial By Error: Australia’s Online GET/CBT Education Program Read More »
By David Tuller, DrPH Saturday, May 12th, is International ME Awareness Day. (It’s also International Fibromyalgia Awareness Day, and the same for Gulf War Illness and Multiple Chemical Sensitivity. But here we’re mostly focused on the first.) This day in the calendar was adopted years ago as an opportunity to promote the visibility of neuro-immune …
Trial By Error: May 12th-International ME Awareness Day Read More »
By David Tuller, DrPH During my week in Perth, I visited Alem Matthees twice. Alem is the patient who successfully fought Queen Mary University of London for access to raw PACE trial data; reanalyses of these data have exposed how the extensive outcome-switching led to the improved results reported by the investigators.
